Innoviva
A diversified holding company with a portfolio of royalties that include respiratory assets partnered with GSK, as well as a growing portfolio of innovative healthcare investments and assets in areas of significant unmet medical need.
In July 2022, Innoviva announced its acquisition of La Jolla Pharmaceuticals Company in a deal with an implied enterprise value of approximately $149 million.
This acquisition strengthened Innoviva’s portfolio in infectious diseases, anchored by the company’s purchase of Entasis Therapeutics Holdings, an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.
Latest Innoviva News & Features
2 November 2023
8 August 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze